Motif Bio, the clinical stage biopharmaceutical company specialising in developing novel antibiotics, has granted a total of 1,500,000 options to purchase ordinary shares of 1 pence each of Motif Bio (“Ordinary Shares”) to Robert Dickey IV, Chief Financial Officer.
The options vest over a four year period and have an exercise price of 25.5 pence per Ordinary Share, being the closing price of the Ordinary Shares on 17 January 2017, the date of grant of the options, the company said in its press release on Wednesday.